Literature DB >> 19690516

Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis.

Jeroen Geurts1, Leo A B Joosten, Nozomi Takahashi, Onno J Arntz, Anton Glück, Miranda B Bennink, Wim B van den Berg, Fons A J van de Loo.   

Abstract

The promoter regions of genes that are differentially regulated in the synovial membrane during the course of rheumatoid arthritis (RA) represent attractive candidates for application in transcriptionally targeted gene therapy. In this study, we applied an unbiased computational approach to define proximal-promoters from a gene expression profiling study of murine experimental arthritis. Synovium expression profiles from progressing stages of collagen-induced arthritis (CIA) were classified into six distinct groups using k-means clustering. Using an algorithm based on local over-representation and comparative genomics, we identified putatively functional transcription factor-binding sites (TFBS) in TATA-dependent proximal-promoters. Applying a filter based on spacing between TATA box and transcription start site (TSS) combined with the presence of over-represented nuclear factor kappaB (NFkappaB), AP-1, or CCAAT/enhancer-binding protein beta (C/EBPbeta) sites, 382 candidate murine and human promoters were reduced to 66, corresponding to 45 genes. In vitro, 9 out of 10 computationally defined promoter regions conferred cytokine-inducible expression in murine cells and human synovial fibroblasts. Under these conditions, the serum amyloid A3 (Saa3) promoter showed the strongest transcriptional induction and strength. We applied this promoter for driving therapeutically efficacious levels of the interleukin-1 receptor antagonist (Il1rn) in a disease-regulated fashion. These results demonstrate the value of bioinformatics for guiding the selection of endogenous promoters for transcriptionally targeted gene therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690516      PMCID: PMC2835043          DOI: 10.1038/mt.2009.182

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

Review 1.  DNA binding sites: representation and discovery.

Authors:  G D Stormo
Journal:  Bioinformatics       Date:  2000-01       Impact factor: 6.937

Review 2.  The RNA polymerase II core promoter: a key component in the regulation of gene expression.

Authors:  Jennifer E F Butler; James T Kadonaga
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

3.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles.

Authors:  Albin Sandelin; Wynand Alkema; Pär Engström; Wyeth W Wasserman; Boris Lenhard
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

4.  AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis.

Authors:  Z Han; D L Boyle; A M Manning; G S Firestein
Journal:  Autoimmunity       Date:  1998       Impact factor: 2.815

5.  Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee.

Authors:  A C Bakker; L A Joosten; O J Arntz; M M Helsen; A M Bendele; F A van de Loo; W B van den Berg
Journal:  Arthritis Rheum       Date:  1997-05

6.  Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.

Authors:  R L Smeets; L A B Joosten; O J Arntz; M B Bennink; N Takahashi; H Carlsen; M U Martin; W B van den Berg; F A J van de Loo
Journal:  Arthritis Rheum       Date:  2005-07

7.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis.

Authors:  J Geurts; O J Arntz; M B Bennink; L A B Joosten; W B van den Berg; F A J van de Loo
Journal:  Gene Ther       Date:  2007-09-13       Impact factor: 5.250

9.  C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene.

Authors:  A C Bakker; F A J van de Loo; L A B Joosten; O J Arntz; A W Varley; R S Munford; W B van den Berg
Journal:  Arthritis Rheum       Date:  2002-06

10.  Programming gene expression with combinatorial promoters.

Authors:  Robert Sidney Cox; Michael G Surette; Michael B Elowitz
Journal:  Mol Syst Biol       Date:  2007-11-13       Impact factor: 11.429

View more
  8 in total

1.  Rho kinase inhibitor Y-27632 prolongs the life span of adult human keratinocytes, enhances skin equivalent development, and facilitates lentiviral transduction.

Authors:  Ellen H van den Bogaard; Diana Rodijk-Olthuis; Patrick A M Jansen; Ivonne M J J van Vlijmen-Willems; Piet E van Erp; Irma Joosten; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  Tissue Eng Part A       Date:  2012-06-05       Impact factor: 3.845

2.  Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis.

Authors:  Helder I Nakaya; Joy Gardner; Yee-Suan Poo; Lee Major; Bali Pulendran; Andreas Suhrbier
Journal:  Arthritis Rheum       Date:  2012-11

3.  A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.

Authors:  Maria C Subang; Rewas Fatah; Carly Bright; Patricia Blanco; Mariana Berenstein; Ying Wu; Osvaldo L Podhajcer; Paul G Winyard; Yuti Chernajovsky; David Gould
Journal:  J Mol Med (Berl)       Date:  2011-10-30       Impact factor: 4.599

4.  Serum Amyloid A3 Gene Expression in Adipocytes is an Indicator of the Interaction with Macrophages.

Authors:  Yohei Sanada; Takafumi Yamamoto; Rika Satake; Akiko Yamashita; Sumire Kanai; Norihisa Kato; Fons Aj van de Loo; Fusanori Nishimura; Philipp E Scherer; Noriyuki Yanaka
Journal:  Sci Rep       Date:  2016-12-08       Impact factor: 4.379

5.  The serum amyloid A3 promoter-driven luciferase reporter mice is a valuable tool to image early renal fibrosis development and shows the therapeutic effect of glucosyl-hesperidin treatment.

Authors:  Thanutchaporn Kumrungsee; Taishi Kariya; Kotaro Hashimoto; Takayuki Koyano; Nao Yazawa; Takao Hashimoto; Yohei Sanada; Makoto Matsuyama; Yusuke Sotomaru; Hiroaki Sakurai; Fons A J van de Loo; Noriyuki Yanaka
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

6.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

7.  Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane.

Authors:  Mathijs G A Broeren; Marieke de Vries; Miranda B Bennink; Onno J Arntz; Peter L E M van Lent; Peter M van der Kraan; Wim B van den Berg; Frank H J van den Hoogen; Marije I Koenders; Fons A J van de Loo
Journal:  Arthritis Res Ther       Date:  2016-08-12       Impact factor: 5.156

8.  Imaging, myeloid precursor immortalization, and genome editing for defining mechanisms of leukocyte recruitment in vivo.

Authors:  Sandra Gran; Lisa Honold; Olesja Fehler; Stefanie Zenker; Sarah Eligehausen; Michael T Kuhlmann; Edwin Geven; Martijn van den Bosch; Peter van Lent; Christoph Spiekermann; Sven Hermann; Thomas Vogl; Michael Schäfers; Johannes Roth
Journal:  Theranostics       Date:  2018-03-23       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.